ADMA — ADMA Biologics Inc

Is ADMA overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Biotechnology

Overbought As of August 19, 2026

ADMA Biologics Inc (ADMA) currently reads Overbought on the MarketMoodz overbought/oversold meter, as of August 19, 2026. The Healthcare name (Biotechnology) last closed at $10.05. The rating moved from Neutral to Overbought on August 19, 2026.

See all overbought Healthcare stocks →

AI analysis

ADMA Biologics Inc (ADMA) is a small‑cap plasma‑derived biologics company with a focused commercial portfolio that generates revenue from specialty immunoglobulin products. The company benefits from a technical niche in plasma‑derived therapeutics and established manufacturing/supply relationships, while sector themes that expand demand for specialized biologics manufacturing are supportive. Near‑term fundamentals are clouded by payer and reimbursement pressure, supply chain and plasma collection sensitivity, potential capital needs, and limited near‑term public disclosure. Given the mixed catalysts and elevated execution risk, the outlook favors monitoring operational execution, margin trends, and any incremental regulatory or commercial updates that would materially change the revenue trajectory.

Key factors

  • Revenue driven by plasma‑derived immunoglobulin products with niche demand in specialty indications
  • Established manufacturing and supply relationships support commercial distribution but capacity and scale remain constrained versus large peers
  • Sector tailwinds for biologics and CDMO/CRO suppliers could indirectly benefit the company through increased demand for specialized manufacturing and analytical services
  • Payer dynamics and margin pressure across healthcare create uncertainty around reimbursement and pricing for specialty biologics
  • Limited public-disclosure activity in the immediate window increases near-term informational uncertainty for investors
  • Market conditions over the past several hours show balanced risk appetite, reducing short-term volatility risk from macro surprises

Risks

  • Reimbursement and payer pressure could compress pricing or access for plasma‑derived therapies
  • Concentration risk: reliance on a narrow product set and limited customer base could amplify revenue volatility
  • Supply chain and plasma collection constraints or shortages could impair production and shipments
  • Regulatory or quality issues at manufacturing sites could cause disruptions or recalls
  • Need for additional capital to fund growth or operations could lead to dilution or higher financing costs
  • Competitive pressure from larger biologics manufacturers and emerging therapies could erode market share
  • Low liquidity and small‑cap volatility can cause outsized share price moves unrelated to fundamentals

Latest MarketMoodz coverage

See today's live rating, score and targets

Members see the live hourly rating for ADMA — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.